πŸ‡ΊπŸ‡Έ FDA
Patent

US 8173615

TRPM-2 antisense therapy

granted A61KA61K31/00A61K31/337

Quick answer

US patent 8173615 (TRPM-2 antisense therapy) held by TEVA PHARMACEUTICAL INDUSTRIES, LTD. expires Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
TEVA PHARMACEUTICAL INDUSTRIES, LTD.
Grant date
Tue May 08 2012 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 03 2032 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
4
CPC classes
A61K, A61K31/00, A61K31/337, A61K31/66, A61K31/704